Table 2.
Type and completeness or reporting
| Total N = 712 |
Part 1 Q4 2011–Q1 2014 N = 191 |
Part 2 Q1 2014–Q1 2016 N = 334 |
Part 3 Q2 2016–Q2 2018 N = 187 |
p value | ||
|---|---|---|---|---|---|---|
| Type of reporting | ||||||
| Report Type | Free text | 77.8% (554) | 97.9% (187) | 67.1% (224) | 76.5% (143) | <0.001 |
| Semi-structured | 3.2% (23) | 0.5% (1) | 3.3% (11) | 5.9% (11) | ||
| Structured (template) | 19.0% (135) | 1.6% (3) | 29.6% (99) | 17.6% (33) | ||
| Items included in report | ||||||
| 1 Morphology | Lesion type reported (polyp, semi-annular, annular) | 66.6% (474) | 51.8% (99) | 67.4% (225) | 80.2% (150) | <0.001 |
| Not reported | 33.4% (238) | 48.2% (92) | 32.6% (109) | 19.8% (37) | ||
| Tumor type reported (solid, mucinous) | 6.6% (47) | 2.1% (4) | 8.4% (28) | 8.0% (15) | 0.013 | |
| Not reported | 93.4% (665) | 97.9% (187) | 91.6% (306) | 92.0% (172) | ||
| 2 Tumor circumference | Specified as from … to … o’clock | 12.4% (88) | 5.8% (11) | 15.6% (52) | 13.4% (25) | <0.001 |
| Only prose description (ventral/dorsal/lateral) | 12.2% (87) | 19.9% (38) | 10.8% (36) | 7.0% (13) | ||
| Not reported | 75.4% (537) | 74.3% (142) | 73.7% (246) | 79.7% (149) | ||
| 3 Height | Reported as measurement from ARJ/anal verge | 92.6% (659) | 88.5% (169) | 92.8% (310) | 96.3% (180) | 0.018 |
| Only prose description (low/mid/upper) | 5.6% (40) | 7.3% (14) | 6.0% (20) | 3.2% (6) | ||
| Not reported | 1.8% (13) | 4.2% (8) | 1.2% (4) | 0.5% (1) | ||
| 4 Length | Reported in cm/mm | 90.3% (643) | 87.4% (167) | 91.0% (304) | 92.0% (172) | 0.274 |
| Not reported | 9.7% (69) | 12.6% (24) | 9.0% (30) | 8.0% (15) | ||
| 5 cT-stage | Reported incl. substaging (incl. cT3abcd, cT4ab) | 22.8% (162) | 2.1% (4) | 19.8% (66) | 49.2% (92) | <0.001 |
| Reported without substaging (cT1234) | 65.6% (467) | 70.2% (134) | 73.4% (245) | 47.1% (88) | ||
| Not explicitly mentioned but can be derived from prose description* | 10.3% (73) | 25.1% (48) | 5.7% (19) | 3.2% (6) | ||
| Not reported | 1.4% (10) | 2.6% (5) | 1.2% (4) | 0.5% (1) | ||
| 6 Anal sphincter involvement | Reported | 7.9% (56) | 3.7% (7) | 8.4% (28) | 11.2% (21) | 0.004 |
| Not reported | 92.1% (656) | 96.3% (184) | 91.6% (306) | 88.7% (166) | ||
| in low tumors | 33.7% (240) | 42.9% (82) | 31.4% (105) | 28.3% (53) | ||
| in mid/high tumors (N/A) | 58.4% (416) | 53.4% (102) | 60.2% (201) | 60.4% (113) | ||
| 7 MRF invasion | Reported | 81.4% (580) | 73.3% (140) | 82.9% (277) | 87.2% (163) | 0.032 |
| Not reported | 16.6% (118) | 24.1% (46) | 15.0% (50) | 11.7% (22) | ||
| in cT3-4 tumors# | 8.6% (61) | 11.0% (21) | 7.5% (25) | 8.0% (15) | ||
| in cT1-2 tumors (N/A)# | 7.4% (53) | 12.6% (24) | 6.9% (23) | 3.2% (6) | ||
| Inconclusive** | 2.0% (14) | 2.6% (5) | 2.1% (7) | 1.1% (2) | ||
| 8 Tumor-MRF margin | Reported | 59.7% (426) | 48.7% (93) | 65.6% (219) | 61.0% (114) | 0.004 |
| Not reported | 40.2% (286) | 51.3% (98) | 34.5% (115) | 39.0% (73) | ||
| in cT3-4 tumors# | 28.2% (201) | 36.1% (69) | 22.2% (74) | 31.0% (58) | ||
| in cT1-2 tumors (N/A)# | 11.4% (81) | 14.7% (28) | 11.7% (39) | 7.5% (14) | ||
| 9 cN-stage | Reported incl. substaging (cN0/cN1abc/cN2ab) | 1.3% (9) | 0.5% (1) | 2.4% (8) | 0% (0) | <0.001 |
| Reported as cN0/N1/N2 | 74.2% (528) | 58.1% (111) | 74.6% (249) | 89.8% (168) | ||
| Reported as cN-/N+ | 6.3% (45) | 1.6% (3) | 10.8% (36) | 3.2% (6) | ||
| Not explicitly mentioned but can be derived from prose description of number of suspicious nodes | 11.1% (79) | 19.4% (37) | 9.0% (30) | 6.4% (12) | ||
| Not reported | 7.2% (51) | 20.4% (39) | 3.3% (11) | 0.5% (1) | ||
| 10 Number of N+ nodes (in cN+ cases) | Reported | 54.9% (391) | 41.9% (80) | 57.5% (192) | 63.6% (119) | 0.014 |
| Not reported | 12.9% (92) | 15.7% (30) | 13.5% (45) | 9.1% (17) | ||
| 11 Total number of nodes | Reported | 9.3% (66) | 10.5% (20) | 8.1% (27) | 10.2% (19) | 0.588 |
| Not reported | 90.7% (646) | 89.5% (171) | 91.9% (307) | 89.8% (168) | ||
| 12 Extramesorectal (lateral) nodes | Reported | 52.2% (372) | 27.7% (53) | 63.5% (212) | 57.2% (107) | <0.001 |
| Not reported | 47.8% (340) | 72.3% (138) | 36.6% (122) | 42.8% (80) | ||
| in cN+ cases# | 27.7% (197) | 39.3% (75) | 21.0% (70) | 27.8% (52) | ||
| in cN- cases (N/A)# | 14.5% (103) | 15.7% (30) | 13.5% (45) | 15.0% (28) | ||
| 13 Tumor deposits | Reported | 1.3% (9) | 0.5% (1) | 1.5% (5) | 1.6% (3) | 0.561 |
| Not reported | 98.7% (703) | 99.5% (190) | 98.5% (329) | 98.4% (184) | ||
| 14 EMVI | Reported | 28.0% (200) | 4.7% (9) | 36.2% (121) | 37.4% (70) | <0.001 |
| Not reported | 72.0% (512) | 95.3% (182) | 63.8% (213) | 62.5% (117) | ||
| in cT3-4 tumors# | 54.4% (387) | 72.8% (139) | 46.4% (155) | 49.7% (93) | ||
| in T1-2 tumors (N/A)# | 16.3% (116) | 19.9% (38) | 16.5% (55) | 12.3% (23) | ||
*Examples of prose descriptions from which cT-stage could be derived: “Tumor limited to bowel wall,” “Tumor extending into perirectal fat,” “Tumor growing into peritoneum,” etc
**MRF invasion was categorized as inconclusive in case of unclear descriptions such as “close margin”
#In some cases, sub-categorization was not feasible not feasible due to missing information on cT-stage or cN-stage, respectively.